With patented Switchblocker™ and PrimerSwitch™ technologies, Tsunami and Riptide assays deliver high sensitivity and accuracy for demanding applications.
Less expensive and faster than NGS, Tsunami™ assays are a good choice when fast answers are critical. With 10X higher sensitivity than NGS, your team will likely also report fewer QNS results.
Tsunami oncology assays are:
EGFR Del 19, EGFR L858, EGFR T790M, Pan Assay Control
Research Use Only, Not intended for Diagnostics, Not Approved by FDA
Riptide™ pharmacogenomic assays are developed from pharmacuetical guidelines and are correlated to genes that regulate or impact compound effectiveness including:
| Gene | Compound | Note |
|---|---|---|
| SLCO1B1 & ABCG2 | Statins | CPIC A/B |
| ACE2 I/D intron 16 rs4646994 | Lisinopril | |
| DIO2 | Levothyroxine | |
| CYP3A5 (c.219-237A>G) | Amlodipine, Levothyroxine |
Research Use Only, Not intended for Diagnostics, Not Approved by FDA
Aegea provides a range of products and services, including research-use-only (RUO) kits, and custom assay development. These offerings are designed to integrate seamlessly into existing laboratory workflows, enhancing the sensitivity and specificity of molecular analyses.
Aegea’s solutions are tailored for a diverse clientele, including pharmaceutical and biotech companies, life science researchers, and clinical laboratories developing new technologies and assays for DNA mutation detection. Organizations seeking to improve the detection of rare genetic events or to develop multiplexed assays will find Aegea’s technologies particularly advantageous.
Yes. Aegea collaborates with clients to develop custom assays and adapt its technologies to various platforms. This collaborative approach ensures that the assays meet specific research or clinical needs.
To explore collaboration opportunities, you can contact us here LINK. We welcome partnerships that aim to advance molecular diagnostics and personalized medicine.
Best-in-class Switch-Blocker technology is unmatched in analytic sensitivity for rare DNA mutation detection. The company owns a suite of nucleic acid amplification technologies and a robust portfolio of 11 issued U.S. patents, and a proven track record in clinical research and validation.
